Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;22(8):1286-1326.
doi: 10.2174/1570159X22666240124114126.

Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Carlo Maria Bellanca  1   2 , Egle Augello  1   2 , Alice Mariottini  3 , Gabriele Bonaventura  4 , Valentina La Cognata  4 , Giulia Di Benedetto  1   2 , Anna Flavia Cantone  1 , Giuseppe Attaguile  1 , Rosaria Di Mauro  1 , Giuseppina Cantarella  1 , Luca Massacesi  3 , Renato Bernardini  1   2
Affiliations
Review

Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

Carlo Maria Bellanca et al. Curr Neuropharmacol. 2024.

Abstract

Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades, remarkable results have been achieved in the treatment of MS, particularly in the relapsing- remitting (RRMS) form, thus improving the long-term outcome for many patients. As deeper knowledge of MS pathogenesis and respective molecular targets keeps growing, nowadays, several lines of disease-modifying treatments (DMT) are available, an impressive change compared to the relative poverty of options available in the past. Current MS management by DMTs is aimed at reducing relapse frequency, ameliorating symptoms, and preventing clinical disability and progression. Notwithstanding the relevant increase in pharmacological options for the management of RRMS, research is now increasingly pointing to identify new molecules with high efficacy, particularly in progressive forms. Hence, future efforts should be concentrated on achieving a more extensive, if not exhaustive, understanding of the pathogenetic mechanisms underlying this phase of the disease in order to characterize novel molecules for therapeutic intervention. The purpose of this review is to provide a compact overview of the numerous currently approved treatments and future innovative approaches, including neuroprotective treatments as anti-LINGO-1 monoclonal antibody and cell therapies, for effective and safe management of MS, potentially leading to a cure for this disease.

Keywords: Multiple sclerosis; approved drugs; clinical trials; disease-modifying therapies; future perspective; off-label treatments; stem cells..

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Similar articles

See all similar articles

References

    1. Didonna A., Oksenberg J.R. In: Zagon IS, McLaughlin PJ, editors. Codon Publications; Brisbane: 2017. The Genetics of Multiple Sclerosis. - DOI - PubMed
    1. Belbasis L., Bellou V., Evangelou E., Ioannidis J.P.A., Tzoulaki I. Environmental risk factors and multiple sclerosis : An umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263–273. doi: 10.1016/S1474-4422(14)70267-4. - DOI - PubMed
    1. Reich D.S., Lucchinetti C.F., Calabresi P.A. Multiple Sclerosis. N. Engl. J. Med. 2018;378(2):169–180. doi: 10.1056/NEJMra1401483. - DOI - PMC - PubMed
    1. Multiple Sclerosis: Facts, Statistics, and You. Available at: https://www.healthline.com/health/multiple-sclerosis/facts-statistics-in....
    1. Adelman G., Rane S.G., Villa K.F. The cost burden of multiple sclerosis in the United States : A systematic review of the literature. J. Med. Econ. 2013;16(5):639–647. doi: 10.3111/13696998.2013.778268. - DOI - PubMed
-